Thomas Meier Email

Chief Scientific Officer . Santhera Pharmaceuticals

Pratteln,

Location

LinkedIn

Current Roles

Employees:
122
Revenue:
$24.5M
About
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular diseases with high unmet medical need. The Company has an exclusive license from ReveraGen for all indications worldwide to AGAMREE® (vamorolone), a dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy (DMD) as an alternative to standard corticosteroids. AGAMREE for the treatment of DMD is approved in the U.S. by the Food and Drug Administration (FDA), in the EU by the European Medicines Agency (EMA), and in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA). Santhera has out-licensed rights to AGAMREE for North America to Catalyst Pharmaceuticals, Inc. and for China to Sperogenix Therapeutics. \n\nFor more information, please visit the Company's website at www.santhera.com
Santhera Pharmaceuticals Address

Pratteln, null
ch
Santhera Pharmaceuticals Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.